Kanvas buys Federation Bio’s assets to scale microbiome-based therapeutics
The microbiome mapping technology provider has acquired the assets to scale the discovery, development, and production of microbiome-based…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Oct 23
The microbiome mapping technology provider has acquired the assets to scale the discovery, development, and production of microbiome-based…
12 Oct 23
Zynerba Pharmaceuticals stands at the forefront of producing pharmaceutical-grade transdermal cannabinoid therapies specifically tailored for orphan neuropsychiatric disorders
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Oct 23
Through the acquisition, BMS will add Mirati’s lung cancer drug Krazati to its commercial portfolio, along with several…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 23
The acquisition will strengthen Kyowa Kirin’s portfolio with several HSC gene therapies targeting serious diseases, maximise the value…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 23
The acquisition will allow Sharp to provide a comprehensive, fully integrated solution for small-to-medium-scale sterile injectable services within…
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Oct 23
Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
03 Oct 23
The acquisition equips Clade with preclinical cell therapy programmes, a g/d TCR discovery engine, and cell enhancement technologies…
27 Sep 23
Intercept is engaged in developing and commercialising novel therapeutics for rare and serious liver diseases, and its acquisition…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Sep 23
The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates